The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes
Joint Authors
Heitkötter, Birthe
Huss, Sebastian
van Strijp, Dianne
de Witz, Christiane
Bögemann, Martin
Baillie, George S.
Houslay, Miles D.
Hoffmann, Ralf
Vos, Pieter C.
den Biezen-Timmermans, Eveline
van Brussel, Anne
Wrobel, Janneke
Tennstedt, Pierre
Schlomm, Thorsten
Semjonow, Axel
Bangma, Chris
Source
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-07-26
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Purpose.
To further validate the prognostic power of the biomarker PDE4D7, we investigated the correlation of PDE4D7 scores adjusted for presurgical clinical variables with longitudinal postsurgical biological outcomes.
Methods.
RNA was extracted from biopsy punches of resected tumors (550 patients; RP cohort) and diagnostic needle biopsies (168 patients; DB cohort).
Cox regression and survival were applied to correlate PDE4D7 scores with patient outcomes.
Logistic regression was used to combine the clinical CAPRA score with PDE4D7.
Results.
In univariate analysis, the PDE4D7 score was significantly associated with PSA recurrence after prostatectomy in both studied patient cohorts’ analysis (HR 0.53; 95% CI 0.41-0.67; p<1.0E-04 and HR 0.47; 95% CI 0.33-0.65; p<1.0E-04, respectively).
After adjustment for the presurgical clinical variables preoperative PSA, PSA density, biopsy Gleason, clinical stage, percentage tumor in the biopsy (data only available for RP cohort), and percentage of positive biopsies, the HR was 0.49 (95% CI 0.38-0.64; p<1.0E-04) and 0.43 (95% CI 0.29-0.63; p<1.0E-04), respectively.
The addition of the PDE4D7 to the clinical CAPRA score increased the AUC by 5% over the CAPRA score alone (0.82 versus 0.77; p=0.004).
This combination model stratified 14.6% patients of the DB cohort to no risk of biochemical relapse (NPV 100%) over a follow-up period of up to 15 years.
Conclusions.
The PDE4D7 score provides independent risk information for pretreatment risk stratification.
Combining CAPRA with PDE4D7 scores significantly improved the clinical risk stratification before surgery.
American Psychological Association (APA)
van Strijp, Dianne& de Witz, Christiane& Vos, Pieter C.& den Biezen-Timmermans, Eveline& van Brussel, Anne& Wrobel, Janneke…[et al.]. 2018. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer،Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1212441
Modern Language Association (MLA)
van Strijp, Dianne…[et al.]. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer No. 2018 (2018), pp.1-11.
https://search.emarefa.net/detail/BIM-1212441
American Medical Association (AMA)
van Strijp, Dianne& de Witz, Christiane& Vos, Pieter C.& den Biezen-Timmermans, Eveline& van Brussel, Anne& Wrobel, Janneke…[et al.]. The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer. 2018. Vol. 2018, no. 2018, pp.1-11.
https://search.emarefa.net/detail/BIM-1212441
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1212441